Clinical Trials

184 enrolled

Breast Neoplasms

NCT06459180 2026-03-13

TroFuse-020

686 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

90 enrolled

Breast Neoplasms

NCT06632327 2026-03-04

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

1,100 enrolled

Lung Neoplasms

NCT07007559 2026-02-03

ASPEN-09

80 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05300282 2026-01-28

FIL_A-BEGEV

122 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT06576635 2026-01-20

LUNG-05

Phase NA Recruiting

29 enrolled

NSCLC

NCT02813135 2026-01-16

ESMART

472 enrolled

Tumor-Agnostic

Neoplasms

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

300 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT06690840 2026-01-05

AZALEA

45 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06908993 2025-12-17

COMET

133 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07088263 2025-12-11

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

192 enrolled

Breast Neoplasms

NCT03618550 2025-12-02

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

257 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT06079983 2025-09-12

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

400 enrolled

Breast Neoplasms

NCT06023641 2025-08-19

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

135 enrolled

Sarcoma

Rhabdomyosarcoma

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

200 enrolled

Fludzoparib" and Anti-angiogenic

NCT06500494 2025-07-24

VINOREAL

Recruiting

368 enrolled

Advanced Breast Cancer

NCT06377566 2025-04-20

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

71 enrolled

Lymphoid

Hodgkin Disease

NCT06143553 2024-11-29

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

168 enrolled

Breast Neoplasms

NCT06102824 2024-11-25

ORIENTA

252 enrolled

HER2-negative Breast Cancer

NCT05487391 2024-10-15

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

632 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06176534 2024-08-20

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

240 enrolled

Advanced Breast Cancer

NCT04625907 2024-05-23

FaR-RMS

1,672 enrolled

Sarcoma

Rhabdomyosarcoma

NCT06202261 2024-03-12

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

154 enrolled

Breast Neoplasms

NCT06268652 2024-02-20

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

302 enrolled

Breast Neoplasms

NCT05856383 2023-05-12

HER2-VIP

Recruiting

100 enrolled